ACH

Accendra Health Inc
NYSEHEALTHCAREMEDICAL DISTRIBUTION

Key Statistics

Market Cap
$15.62M
P/E Ratio
—
EPS
$-1.60
Beta
1.62
52W High
$4.69
52W Low
$0.19
50-Day MA
$0.62
200-Day MA
$2.19
Dividend Yield
—
Profit Margin
-6.72%
Forward P/E
6.94
PEG Ratio
0.70

About Accendra Health Inc

Aluminum Corporation of China Limited, manufactures and sells alumina, primary aluminum and energy products in the People's Republic of China. The company is headquartered in Beijing, the People's Republic of China.

Official WebsiteUSAFY End: December

Fundamentals

Revenue (TTM)$2.55B
Gross Profit (TTM)$1.13B
EBITDA$264.79M
Operating Margin1.14%
Return on Equity-198.40%
Return on Assets0.69%
Revenue/Share (TTM)$33.26
Book Value$-7.21
Price-to-Book1.07
Price-to-Sales (TTM)0.01
EV/Revenue0.679
EV/EBITDA6.79
Quarterly Earnings Growth (YoY)0.00%
Quarterly Revenue Growth (YoY)-13.70%
Shares Outstanding$76.91M
Float$57.55M
% Insiders7.28%
% Institutions82.41%

Historical Volatility

HV 10-Day
231.38%
HV 20-Day
204.18%
HV 30-Day
171.28%
HV 60-Day
142.37%
HV Rank
—

Volatility is currently expanding

Analyst Ratings

Consensus ($1.26 target)
3
Hold
2
Strong Sell

Latest News

Accendra Health, Inc. (ACH) Q3 2026 Earnings Call Transcript

Accendra Health, Inc. ( ACH ) Q3 2026 Earnings Call November 5, 2026 5:00 PM EST Company Participants Will Parrish - VP of Strategy, Corporate Development, & IR Kenneth Gardner-Smith - President, CEO & Director Jonathan Leon - Executive VP, CFO & Corporate Treasurer Conference Call Participants Rishi Parekh - JPMorgan Chase & Co, Research Division Presentation Operator Good evening, and thank you for standing by. Welcome to Accendra Health's Third Quarter 2026 Earnings Conference Call.

Seeking Alpha11/6/2026Neutral
Accendra Health Reports Third Quarter 2026 Financial Results

RICHMOND, Va.--(BUSINESS WIRE)--Accendra Health, Inc. (NYSE: ACH) (the Company) today reported financial results for the third quarter ended September 30, 2026. Unless otherwise noted, the results herein reflect the Company's continuing operations, which represent what was previously the Patient Direct segment and certain functional operations. “Over the several weeks since I started, a number of themes have become clear to me. We have strong brands, favorable end markets, and a teammate popula.

Business Wire11/5/2026Neutral
Accendra Health Announces Extension of $150 Million Receivables Sale Program To 2029

RICHMOND, Va.--(BUSINESS WIRE)--Accendra Health, Inc. (NYSE: ACH) (the “Company”) today announced that it executed an amendment to its Receivables Purchase Agreement (the “Receivables Sale Program”) on October 29, 2026. The amendment, among other things, extends the Scheduled Termination Date of the facility to October 2029, and the $150 million size of the Receivables Sale Program is unchanged. “We are pleased to have worked with our banking partner to extend the Receivables Sale Program until.

Business Wire11/2/2026Neutral
Accendra Health Receives Continued Listing Standard Notice from NYSE Regarding Market Capitalization and Stockholders' Equity; Intends to Submit Business Plan and Return to Compliance with NYSE Listing Standard​

RICHMOND, Va.--(BUSINESS WIRE)--Accendra Health, Inc. (NYSE: ACH) (the Company) today announced that on October 27, 2026, it received a notice (the “Notice”) from the New York Stock Exchange (the “NYSE”) notifying the Company that it is not in compliance with Section 802.01B of the NYSE's continued listing standards that the Company have an average market capitalization of not less than $50.0 million over a consecutive 30 trading-day period and stockholders' equity of not less than $50.0 millio.

Business Wire10/30/2026Neutral
Accendra Health Names Kenneth Gardner-Smith as President and Chief Executive Officer to Lead the Company's Next Chapter of Growth

RICHMOND, Va.--(BUSINESS WIRE)--Accendra Health, Inc. (NYSE: ACH) (the “Company”) today named Kenneth Gardner-Smith as the Company's next President and Chief Executive Officer. Gardner-Smith, who has served on the Company's Board of Directors since March 2022, is expected to assume the role early in the fourth quarter 2026. He will succeed Edward A. Pesicka, who announced his intent to retire in August. Gardner-Smith brings deep experience running large-scale patient care operations and guiding.

Business Wire9/17/2026Neutral
Accendra Health Updates on Capital Allocation and CEO Succession Timing Plans

RICHMOND, Va.--(BUSINESS WIRE)--Accendra Health (the “Company”) is providing an update on its capital allocation plans and the timeline for the replacement of its chief executive officer. Given recent market conditions, the Company has determined that it is in the best interest of stakeholders not to put in place an at-the-market issuance program. The program was intended to allow the Company to opportunistically issue modest amounts of equity over time, with the proceeds to be used to reduce o.

Business Wire8/17/2026Neutral
Accendra Health Announces Adoption of Tax Asset Preservation Plan To Protect Long Term Shareholder Value

RICHMOND, Va.--(BUSINESS WIRE)--Accendra Health, Inc. (NYSE: ACH) (the Company) announced today that its Board of Directors adopted a Section 382 Rights Agreement (the “Tax Asset Preservation Plan”) designed to protect long-term shareholder value by facilitating the Company's ability to preserve its net operating loss carryforwards (“NOLs”) and certain other tax attributes. A company generally experiences an ownership change if the percentage of the value of its stock owned by certain “5-percen.

Business Wire8/10/2026Neutral

Turn research into an automated options-selling system

Tiblio connects your broker and runs your put-and-call-writing strategy for you — on ACH and any ticker you trade — then tracks every position and per-strategy win rate.

See how it works

More HEALTHCARE Stocks

Data last updated: 11/7/2026